Your browser is no longer supported. Please, upgrade your browser.
Olema Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)- Insider Own9.64% Shs Outstand39.33M Perf Week3.82%
Market Cap1.24B Forward P/E- EPS next Y-2.70 Insider Trans-1.55% Shs Float35.73M Perf Month24.26%
Income- PEG- EPS next Q-0.41 Inst Own88.30% Short Float5.40% Perf Quarter-34.45%
Sales- P/S- EPS this Y-455.80% Inst Trans0.99% Short Ratio9.12 Perf Half Y-34.59%
Book/sh8.29 P/B3.61 EPS next Y-59.80% ROA- Target Price- Perf Year-
Cash/sh7.90 P/C3.79 EPS next 5Y- ROE- 52W Range19.41 - 60.27 Perf YTD-37.79%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-50.37% Beta-
Dividend %- Quick Ratio62.60 Sales past 5Y- Gross Margin- 52W Low54.10% ATR1.81
Employees36 Current Ratio62.60 Sales Q/Q- Oper. Margin- RSI (14)58.72 Volatility5.79% 6.86%
OptionableYes Debt/Eq0.00 EPS Q/Q-355.50% Profit Margin- Rel Volume2.25 Prev Close28.81
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume211.31K Price29.91
Recom1.50 SMA2011.94% SMA504.60% SMA200-22.51% Volume461,005 Change3.82%
Dec-14-20Initiated JP Morgan Overweight $52
Dec-14-20Initiated Jefferies Buy $70
Dec-14-20Initiated Cowen Outperform
Dec-14-20Initiated Canaccord Genuity Buy $60
May-18-21 04:05PM  
May-11-21 04:05PM  
Apr-07-21 07:30AM  
Apr-06-21 07:30AM  
Mar-17-21 04:05PM  
Mar-10-21 04:45PM  
Feb-23-21 07:00AM  
Feb-19-21 04:59AM  
Dec-31-20 03:42PM  
Dec-17-20 07:00AM  
Dec-07-20 07:39AM  
Dec-03-20 05:18PM  
Nov-23-20 04:01PM  
Nov-20-20 01:33PM  
Nov-19-20 06:39PM  
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Horn KinneyCHIEF BUSINESS OFFICERJun 10Option Exercise2.065,25110,8387,041Jun 11 04:30 PM
Horn KinneyCHIEF BUSINESS OFFICERJun 10Sale29.725,251156,0711,790Jun 11 04:30 PM
Horn KinneyCHIEF BUSINESS OFFICERMay 18Option Exercise2.0657,763119,22359,553May 19 08:18 PM
Horn KinneyCHIEF BUSINESS OFFICERMay 18Sale24.1557,7631,394,7691,790May 19 08:18 PM
Cormorant Asset Management, LPFormer 10% OwnerNov 23Buy19.00425,0008,075,0003,270,544Nov 23 04:59 PM
Graham G. WalmsleyDirectorNov 23Buy19.001,160,00022,040,0001,160,000Nov 23 04:35 PM